Pediatric Transplantation

This report of the PHTS Registry provides a comprehensive look at over 30 years of data, highlighting both the longevity and unique aspects of the PHTS registry. It specifically delves into the topic of children single ventricle anatomy showing clear improvements in outcomes for children with cardiomyopathy and CHD alike.

This systematic review highlights elevated cutaneous malignancy risks in pediatric patients after allogeneic HSCT, emphasizing the need for long-term monitoring. The findings underscore the significance of enhanced surveillance and preventive measures to mitigate these risks.

Data from children transplanted from 2010 to 2019 were analyzed using machine learning. Single ventricle congenital heart disease contributed most to overall risk in the first year, followed closely by mechanical circulatory support at the time of transplant and a history of cardiac surgery prior to being listed for transplant.

To evaluate immunization practice among ERN-TransplantChild centers. Cross-sectional questionnaire 27 ERN-TransplantChild centers: 28 SOT programs, 6 HSCT programs. PRE: At the time of transplantation, pediatric candidates were fully immunized (80%–100%) in 57% and 33% of the SOT and HSCT programs. Variations in the time between vaccine administration and admission to the waiting list were reported between the centers. POST: Almost all sites recommended immunization in the post-transplant period, with a time window of 4–8 months for the inactivated vaccines and 16–24 months for MMR and Varicella vaccines. Only five sites administer LAVs after transplantation, with seroconversion evaluated in 80% of cases. The immunization coverage of EU pediatric transplant recipients is still inconsistent and inadequate. This survey is a starting point for developing shared evidence-based immunization protocols for safe vaccination and generating new research studies.